HomeNewsScreenerChartsMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help
Summer Sale Get Elite for just $199.50 Claim Now
Market News Market Pulse Stocks News ETF News Crypto News

Larimar Therapeutics

Contributing Author

Recent Articles by Larimar Therapeutics

1 hour
Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich's Ataxia LRMR GlobeNewswire
Jun-26
Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich's Ataxia LRMR GlobeNewswire
May-14
Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update LRMR -5.12% GlobeNewswire
Apr-30
Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich's Ataxia LRMR -6.45% GlobeNewswire
Mar-19
Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results LRMR GlobeNewswire
Mar-04
Larimar Therapeutics to Participate in Upcoming Investor Conferences in March LRMR GlobeNewswire
Feb-25
Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering LRMR -7.23% GlobeNewswire
Feb-25
Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering LRMR +61.25% LRMR -7.23% GlobeNewswire
Feb-24
Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in FA and Reiterates Planned BLA Submission in June 2026 LRMR +31.32% GlobeNewswire
Dec-18
Larimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference LRMR GlobeNewswire
Nov-05
Larimar Therapeutics Reports Third Quarter 2025 Financial Results LRMR -15.26% GlobeNewswire
Sep-29
Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich's Ataxia LRMR -33.66% GlobeNewswire
Sep-28
Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia LRMR GlobeNewswire
Aug-14
Larimar Therapeutics Reports Second Quarter 2025 Financial Results LRMR +14.52% GlobeNewswire
Jul-31
Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares LRMR GlobeNewswire
Jul-29
Larimar Therapeutics Announces Pricing of Underwritten Public Offering LRMR GlobeNewswire
Jul-29
Larimar Therapeutics Announces Proposed Underwritten Public Offering LRMR GlobeNewswire
Jul-08
Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich's Ataxia LRMR GlobeNewswire
Jun-23
Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich's Ataxia Program LRMR -6.56% GlobeNewswire
Jun-20
Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia LRMR -5.47% GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)